Table 1.
Characteristics of Synthesized Evidence (Meta-Analyses or Systematic Reviews).
| Author, Year | Meta-Analysis | Diagnostic Test | Study Sample | Neuropathological Verification Included/discussed |
|---|---|---|---|---|
| American College of Medical Genetics/American Society of Human Genetics Working Group, 1995 20 | ApoE4 | |||
| Allan et al, 2010 21 | Tau, Aβ1-42, MRI, SPECT, clinical criteria | X | ||
| Andreasen and Blennow, 2005 22 | Tau, Aβ1-42 | |||
| Andreasen et al, 2003 23 | Tau, Aβ1-42 | |||
| Bailey, 2007 24 | Tau, Aβ1-42 | |||
| Bancher et al, 1998 25 | Biomarkers | |||
| Blennow and Hampel, 2003 10 | Biomarkers | 60 studies, 3900 persons with AD, 2200 controls | ||
| Bloudek et al, 2011 3 | x | Tau, Aβ1-42, FDG-PET, SPECT, MRI | 119 studies | |
| Cedazo-Minguez and Winblad, 2010 12 | PET | |||
| Deisenhammer et al, 2009 26 | Tau, Aβ1-42 | |||
| Dewan and Gupta, 1992 27 | Clinical diagnosis, SPECT | x | ||
| Dougall et al, 2004 28 | SPECT | 48 studies, N = 3973 | x | |
| Dubois et al, 2007 6 | MRI, P-tau, T-tau, Aβ1-42, FDG-PET, SPECT | 69 studies, 3900 persons with AD, 2170 controls | x | |
| Durand-Martel et al, 2010 13 | FDG-PET | 47 studies, N = 268 | x | |
| Formichi et al, 2006 29 | Tau, Aβ1-42 | N = 5992 | ||
| Guidelines.gov (EFNS, 2007; SIGN, 2006)a | Clinical diagnosis | x | ||
| Holtzman, 2011 30 | CSF biomarkers | |||
| Jacova et al, 2007 31 | Neuropsychological testing | |||
| Jagust, 2004 32 | PET, SPECT | |||
| Jelic and Kowalski, 2009 16 | EEG | 46 studies | ||
| Jelic and Wahlund, 2007 33 | MRI, PET, EET | |||
| Jellinger, 2010 34 | Biomarkers, clinical diagnosis | x | ||
| Kantarci and Jack, 2003 35 | Neuroimaging | x | ||
| Knopman et al, 2001 4 | Clinical, neuroimaging, biomarkers | x | ||
| Mitchell, 2009 36 | x | MMSE | 34 studies, N = 26 109 | |
| Mitchell, 2009b, 37 | x | Tau | ||
| Mitchell and Brindle, 2003 38 | Tau, Aβ1-42, ApoE4, clinical diagnosis | 5 studies, N = 1287 | x | |
| Patwardhan et al, 2004 39 | x | FDG-PET | 15 studies | |
| Pupi et al, 2005 40 | PET | |||
| Silverman et al, 1999 41 | MRI, SPECT, PET | x | ||
| Sjogren et al, 2003 42 | Tau, Aβ1-42 | |||
| Small and Leiter, 1998 43 | Neuroimagingb | |||
| Sonnen et al, 2008 44 | PET | |||
| Sunderland et al, 2003 45 | x | Aβ1-42 | N = 4624 | |
| Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, 1998 17 | Tau, Aβ1-42, ApoE4 | |||
| Wahlund et al, 2005 46 | MRI | 36 studies | ||
| Waldemar, 1995 47 | SPECT | |||
| Wiltfang et al, 2005 48 | Biomarkers | |||
| Yuan et al, 2009 15 | x | FDG-PET, SPECT, MRI | 24 studies, N = 1112 | |
| Zakzanis, 1998 49 | x | Neuropsychological testing, MRI, PET, SPECT | 27 studies, N = 1278 |
Abbreviations: MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography; PET, positron emission tomography; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; AD, Alzheimer’s disease; FDG, 18F-fluorodeoxyglucose; EEG, electroencephalography; ApoE4, apolipoprotein E4; Aβ1-42, 42 amino acid form of amyloid; P-tau, phosphorylated tau protein; T-tau, total tau protein.
a See http://guidelines.gov/syntheses/synthesis.aspx?id=16413&search=dementia.
b No sensitivity or specificity data reported.